Assignee
SECARNA PHARMACEUTICALS GMBH & CO KG
DE·4 granted patents·11 pending applications·0 citations·filing 2016–2023
Top patents by PatentIndex Score
15 records- 0160US2026043030A1Oligonucleotide for reducing the expression of leucine-rich repeat kinase 2 (LRRK2) and its use for preventing and/or treating human diseasesSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2023·Application pending·0 cites
- 0259US2025059547A1NLRP3 oligonucleotide for use in preventing and/or treating an inflammatory diseaseSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2022·Application pending·0 cites
- 0351US2024076673A1Oligonucleotides reducing the amount of CD73 mRNA and CD73 protein expressionSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2021·Application pending·0 cites
- 0448US11781136B2Oligonucleotide inhibiting the expression of ChopSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2018·Granted Oct 10, 2023·0 cites·12 claims
- 0548US2023183708A1PD-1-specific antisense oligonucleotide and its use in therapySECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2021·Application pending·0 cites
- 0647US2022372482A1Modified antisense oligonucleotide for inhibition of FoxP3 expressionSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 0746US2022372479A1Oligonucleotide based ex vivo cell therapySECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 0842US11666595B2Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancerSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2017·Granted Jun 6, 2023·0 cites·5 claims
- 0941US2023067620A1Inhibitor of metadherin expressionSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 1039US2022220485A1PD-L1 antisense oligonucleotides for use in tumor treatmentSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 1137US10647987B2Approach for treating inflammatory disordersSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2017·Granted May 12, 2020·0 cites·12 claims
- 1236US11959083B2Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39SECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2017·Granted Apr 16, 2024·0 cites·8 claims
- 1336US2018171339A1Agent for the prophylaxis and therapy of viral infectionSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2016·Application pending·0 cites
- 1435US2019330640A1Oligonucleotides inhibiting the expression of nrp1SECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2018·Application pending·0 cites
- 1534US2020163988A1Immunosuppression-Reverting Oligonucleotides Inhibiting the Expression of IDOSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SECARNA PHARMACEUTICALS GMBH & CO KG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →